Amgen Inc (AMGN): Today's Featured Drugs Laggard

Amgen ( AMGN) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.7%. By the end of trading, Amgen fell $1.17 (-1.2%) to $97.49 on average volume. Throughout the day, 4,840,815 shares of Amgen exchanged hands as compared to its average daily volume of 3,826,500 shares. The stock ranged in price between $97.28-$101.72 after having opened the day at $100.20 as compared to the previous trading day's close of $98.66. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 38.6%, Insmed ( INSM), down 18.7%, TherapeuticsMD ( TXMD), down 13.5% and KaloBios Pharmaceuticals ( KBIO), down 7.2%.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $74.2 billion and is part of the health care sector. The company has a P/E ratio of 16.7, below the S&P 500 P/E ratio of 17.7. Shares are up 14.5% year to date as of the close of trading on Friday. Currently there are 9 analysts that rate Amgen a buy, no analysts rate it a sell, and 13 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated.

On the positive front, Onyx Pharmaceuticals ( ONXX), up 51.3%, Bacterin International Holdings ( BONE), up 20.0%, Prima Biomed ( PBMD), up 18.9% and Oxygen Biotherapeutics ( OXBT), up 18.2% , were all gainers within the drugs industry with Valeant Pharmaceuticals International ( VRX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

FDA Approves First 'Biosimilar' for Cancer Treatment

Amgen Builds on a Breakout

How I've Prepared for Hurricane Irma -- and a Market Pullback

How I'm Prepared for Irma -- and a Pullback